GOODIX
27.2.2017 18:53:16 CET | Business Wire | Press release
Goodix (Shanghai Stock Exchange:603160), the premier developer of human interface and biometric solutions for mobile devices, announced today that Huawei P10 and P10 Plus, flagship smartphones of 2017 just launched at Mobile World Congress 2017, are using Invisible Fingerprint Sensor (IFS™) from Goodix.
Huawei’s P10 and P10 Plus smartphones have stylish, integrated screen panel design. The Home key has IFS™ embedded under the screen panel, allowing fingerprint authentication through the glass. IFS™ from Goodix enables the elegant and slim design of P10 and P10 Plus while providing secure and easy-to-use fingerprint authentication. This safeguards the smartphone and secures mobile transactions.
World’s first IFS™ solution meets Huawei’s design needs
Traditionally, a button needs to be placed on the front or at the back of a smartphone in order to install a fingerprint sensor. This means manufacturers need to open a hole on the glass panel for the button. This occupies space, affects the overall phone design and increases the complexity of manufacturing process. Goodix’s IFS™ addresses these issues by seamlessly integrating the sensor right under the glass panel without the need to drill a hole and place a button.
Goodix and Huawei share the same vision of innovating latest technologies to fulfill people’s desires and needs. The longstanding partnership between the two companies is a great success. Prior to the P10 and P10 Plus, a number of Huawei smartphones already use various Goodix’s fingerprint authentication and touchscreen controller solutions. The two companies will continue to innovate to provide safer, more convenient and intelligent technology to mobile users.
IFS™ gives manufacturers more flexibility to develop stylish, slim phone designs. It also supports thick glass panels and improves the water and dust resistance. All this combines to deliver a better user experience and higher reliability.
From R&D to successful commercialization
To authenticate fingerprints through glass panels poses many technical challenges and requires the redesign of circuits and the software algorithm. Goodix has been driving the development process from R&D to commercialization. Since IFS™ was launched in 2014, the company has worked closely with glass panel manufacturers and fingerprint module suppliers to ensure that the functionality, performance, reliability and supply of IFS can meet the various demands of mobile device manufacturers.
The successful commercialization of IFS™ reinforces Goodix as a global leader in biometric technology. This leading position is well recognized by global mobile brands. As of January 2017, Goodix has applied for and received more than 900 patents. The strong R&D capability propels Goodix forward to continue to innovate for mobile users. IFS™ won a Consumer Electronics Show (CES) Innovation Award in 2016, and Goodix was the first Chinese integrated circuit (IC) company to ever win this honor.
About Goodix:
Goodix , a premier developer and provider of fingerprint and touchscreen solutions for mobile phones, tablets and wearables, currently holds a diversified portfolio of fingerprint authentication solutions that provides excellent flexibility to suit the varying preferences from consumers and partners such as Live Finger Detection™, Invisible Fingerprint Sensor (IFS™), Glass-covered and Coating button sensors. In addition, Goodix has been actively involved in assisting Alipay and China UnionPay with reviewing industry standards for fingerprint authentication. An increasing number of top-tier handset manufacturers adopting fingerprints and touch solutions from the company. On October 17, 2016, Goodix was listed on the Shanghai Stock Exchange, the stock code is 603160.
Goodix™ and Invisible Fingerprint Sensor (IFS™) are trademarks of Goodix in China and other countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006232/en/
Contact:
FleishmanHillard, on behalf of Goodix
Alisa Davis, 415-318-4086
Alisa.davis@fleishman.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom